Clinical trials: Intraocular Melanoma
Choroidal Melanoma
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that…
- Trial name
- NCT01251978
- Testing
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New England Retina Associates
Metastatic Uveal Melanoma
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
This phase II trial studies the effect of combining defactinib and VS-6766 in treating patients with uveal melanoma that has spread to other places in the body (metastatic).
- Trial name
- NCT04720417
- Testing
- Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Thomas Jefferson University
Uveal Melanoma
A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp
This Expanded Access Program aims to: 1. Provide access to tebentafusp for mUM patients. 2. Provide access to tebentafusp for patients, who were on the control arm of the randomized controlled Phase II trial (IMCgp100-202) and…
- Trial name
- Non Applicable (NCT04960891)
- Testing
- Tebentafusp
- Sponsor
- Immunocore Ltd
Uveal Melanoma
Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma
Plaque radiotherapy is a common treatment for uveal melanoma. However, local failure has been reported in up to 20% of patients.
- Trial name
- NCT00459849
- Testing
- Intraoperative ultrasonography
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Barnes Retina Institute
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
This phase II trial studies how well glembatumumab vedotin works in treating patients with middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the body (metastatic) or has returned at or near…
- Trial name
- NCT02363283
- Testing
- Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 25 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Ocular Melanoma, Uveal Melanoma
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
This study will evaluate patients who have ocular melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatments and will be followed until death.
- Trial name
- FOCUS (NCT02678572)
- Testing
- Melphalan/HDS
- Where
- 22 sites in United States, Austria and 7 more
- Volunteers
- 102 people
- Sponsor
- Delcath Systems Inc.
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with uveal melanoma that has spread to other places in the body (metastatic).
- Trial name
- NCT01585194
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
Uveal Melanoma, Metastatic Uveal Melanoma
Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group.
- Conditions
- Uveal Melanoma, Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
- Trial name
- SILVER (NCT07063875)
- Testing
- Aldesleukin
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- St Vincent's Hospital, Sydney
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Melanoma, Melanoma, Uveal
MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
Single-centre, first-in-man phase I/II trial to demonstrate safety and efficacy of MAGE-C2/HLA-A2 TCR T cells (MC2 TCR T cells) in advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC).
- Conditions
- Melanoma, Melanoma, Uveal, Head and Neck Cancer
- Trial name
- MC2TCR (NCT04729543)
- Testing
- Adoptive therapy with autologous MC2 TCR T cells
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Uveal Melanoma
Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with…
- Trial name
- NCT00872391
- Testing
- Hypofractionated linear accelerator radiotherapy
- Where
- Austria
- Volunteers
- 155 people
- Sponsor
- Medical University of Vienna
Malignant Melanoma
IMCgp100-401 Rollover Study
IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible participants with advanced melanoma who have previously participated in an IMCgp100 study (parent study).
- Trial name
- NCT02889861
- Testing
- IMCgp100
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Immunocore Ltd
Intraocular Melanoma, Melanoma (Skin)
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00027742
- Testing
- pegylated interferon alfa, temozolomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Intraocular Melanoma
Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma
RATIONALE: Studying samples of bone marrow and blood from patients with cancer may help doctors find out the extent of disease. PURPOSE: This research study is collecting bone marrow and blood samples from patients with…
- Trial name
- NCT00897624
- Testing
- gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
- Volunteers
- 15 people
- Sponsor
- Institut Curie
Stage IV Uveal Melanoma
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
The purpose of this study is to determine whether radiation provided locally to the liver tumor vasculature environment will demonstrate a response of tumor decline. This radiation may cause the tumor cells to die.
- Trial name
- NCT01473004
- Testing
- Sir-Spheres®
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Thomas Jefferson University
Lung Squamous Cell Carcinoma Stage IV, Nonsquamous Nonsmall Cell Neoplasm of Lung
Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
This is a Phase II trial to determine the efficacy and safety of in situ gene therapy and stereotactic body radiation therapy (SBRT) used as a window of opportunity treatment before nivolumab in patients with metastatic squamous…
- Conditions
- Lung Squamous Cell Carcinoma Stage IV, Nonsquamous Nonsmall Cell Neoplasm of Lung, Metastatic Uveal Melanoma
- Trial name
- ENSIGN (NCT02831933)
- Testing
- ADV/HSV-tk, Valacyclovir, SBRT
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Eric Bernicker, MD
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving…
- Trial name
- NCT01814046
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00058279
- Testing
- aldesleukin, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)